Cumberland Pharmaceuticals Inc (CPIX) stock
CPIXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 5/3074% above fair value
$6.63+0.51 (+8.33%)
Close on Nov 12, 2026Market cap $99.34MP/E –Yield –
Cumberland Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Cumberland Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.03M, up 6.4% year over year. For fiscal 2025 it was $5.57M, up 15.6% from the year before. Over ten years it grew 3.8% a year on average. The highest annual figure on record is $7.58M in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.57M | +15.6% |
| FY2024 | Dec 31, 2024 | $4.82M | -17.4% |
| FY2023 | Dec 31, 2023 | $5.83M | -12.8% |
| FY2022 | Dec 31, 2022 | $6.69M | +17.7% |
| FY2021 | Dec 31, 2021 | $5.68M | -1.5% |
| FY2020 | Dec 31, 2020 | $5.77M | -15.9% |
| FY2019 | Dec 31, 2019 | $6.87M | -9.3% |
| FY2018 | Dec 31, 2018 | $7.58M | +77.0% |
| FY2017 | Dec 31, 2017 | $4.28M | +34.2% |
| FY2016 | Dec 31, 2016 | $3.19M | -17.1% |
| FY2015 | Dec 31, 2015 | $3.85M | +13.5% |
| FY2014 | Dec 31, 2014 | $3.39M | -39.6% |
| FY2013 | Dec 31, 2013 | $5.62M | +10.2% |
| FY2012 | Dec 31, 2012 | $5.10M | +1.3% |
| FY2011 | Dec 31, 2011 | $5.03M | +16.2% |
| FY2010 | Dec 31, 2010 | $4.33M | -13.3% |
| FY2009 | Dec 31, 2009 | $4.99M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $772.16K | -7.8% |
| Q1 FY2026 | Mar 31, 2026 | $1.46M | +12.6% |
| Q4 FY2025 | Dec 31, 2025 | $1.55M | +19.9% |
| Q3 FY2025 | Sep 30, 2025 | $1.25M | -4.0% |
| Q2 FY2025 | Jun 30, 2025 | $837.40K | -20.9% |
| Q1 FY2025 | Mar 31, 2025 | $1.30M | +11.8% |
| Q4 FY2024 | Dec 31, 2024 | $1.29M | +2.2% |
| Q3 FY2024 | Sep 30, 2024 | $1.31M | -32.1% |
| Q2 FY2024 | Jun 30, 2024 | $1.06M | -7.5% |
| Q1 FY2024 | Mar 31, 2024 | $1.16M | -22.8% |
| Q4 FY2023 | Dec 31, 2023 | $1.26M | -10.0% |
| Q3 FY2023 | Sep 30, 2023 | $1.92M | +12.3% |
| Q2 FY2023 | Jun 30, 2023 | $1.15M | -37.2% |
| Q1 FY2023 | Mar 31, 2023 | $1.50M | -14.1% |
| Q4 FY2022 | Dec 31, 2022 | $1.41M | -12.8% |
| Q3 FY2022 | Sep 30, 2022 | $1.71M | +17.9% |
| Q2 FY2022 | Jun 30, 2022 | $1.82M | +34.1% |
| Q1 FY2022 | Mar 31, 2022 | $1.75M | +38.8% |
| Q4 FY2021 | Dec 31, 2021 | $1.61M | +15.2% |
| Q3 FY2021 | Sep 30, 2021 | $1.45M | +18.2% |
| Q2 FY2021 | Jun 30, 2021 | $1.36M | -4.3% |
| Q1 FY2021 | Mar 31, 2021 | $1.26M | -27.0% |
| Q4 FY2020 | Dec 31, 2020 | $1.40M | -32.7% |
| Q3 FY2020 | Sep 30, 2020 | $1.23M | -26.5% |
| Q2 FY2020 | Jun 30, 2020 | $1.42M | -17.2% |
| Q1 FY2020 | Mar 31, 2020 | $1.72M | +23.1% |
| Q4 FY2019 | Dec 31, 2019 | $2.08M | -29.4% |
| Q3 FY2019 | Sep 30, 2019 | $1.67M | +28.1% |
| Q2 FY2019 | Jun 30, 2019 | $1.72M | +18.3% |
| Q1 FY2019 | Mar 31, 2019 | $1.40M | -25.3% |
| Q4 FY2018 | Dec 31, 2018 | $2.94M | +116.8% |
| Q3 FY2018 | Sep 30, 2018 | $1.31M | +38.5% |
| Q2 FY2018 | Jun 30, 2018 | $1.45M | +34.2% |
| Q1 FY2018 | Mar 31, 2018 | $1.87M | +108.7% |
| Q4 FY2017 | Dec 31, 2017 | $1.36M | +17.0% |
| Q3 FY2017 | Sep 30, 2017 | $943.16K | +46.3% |
| Q2 FY2017 | Jun 30, 2017 | $1.08M | – |
| Q1 FY2017 | Mar 31, 2017 | $898.36K | – |
| Q4 FY2016 | Dec 31, 2016 | $1.16M | – |
| Q3 FY2016 | Sep 30, 2016 | $644.66K | – |
See a number that looks wrong?